Glumetza: profile and news

Depomed to Announce Fourth Quarter and Year End 2005 Financial ... Feb 28, 2006
In addition, regulatory applications for once daily Glumetza(TM) for the treatment of Type II diabetes have been approved in the US and Canada. ... - Genetic Engineering News,

Stocks Under $10 Weekly Summary Mar 3, 2006
The company has two FDA-approved drugs -- Glumetza for diabetes and Proquin for urinary tract infections -- on the market now that use its Gastric Retention (GR ... - TheStreet.com (subscription),

Depomed Promotes Bret Berner, Ph.D. to Chief Scientific Officer Feb 23, 2006
...recognition of Dr. Berner's significant contributions to the development and approvals of our currently marketed products, ProQuin(R) XR and Glumetza(TM), as ... - Business Wire (press release),

Stocks Under $10 Weekly Summary Feb 24, 2006
Lastly, the company could soon announce a new partner for US distribution of diabetes treatment Glumetza, as its relationship with Biovail (BVF:NYSE) dissolved ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Feb 17, 2006
The company already has two FDA- approved drugs -- Glumetza for diabetes and Proquin for urinary tract infections -- but we expect positive data from its soon ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Feb 10, 2006
DepoMed has two FDA-approved drugs -- Glumetza for diabetes and Proquin for urinary tract infections -- that will be meaningful revenue contributors in 2006 ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Feb 3, 2006
We believe 2006 and 2007 will be strong financial years for DepoMed as its Proquin (for urinary tract infections) and Glumetza (for diabetes) products hit the ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Jan 13, 2006
In addition, DepoMed already has two approved drugs on the market -- Glumetza for diabetes and Proquin XR for urinary tract infections -- and its generic ... - TheStreet.com (subscription),

UPDATE 1-Biovail launches Glumetza in Canada Nov 29, 2005
...(BVF.TO: Quote, Profile, Research) (BVF.N: Quote, Profile, Research) said on Tuesday it had launched Glumetza to treat Type 2 diabetes in Canada. ... - Reuters

Biovail Launches Glumetza to Canadian Physicians Nov 29, 2005
Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Glumetza TM in Canada. Developed in partnership with Depomed, Inc. ... - CCNMatthews (Communiqués de presse),

Biovail Launches Glumetza to Canadian Physicians Nov 29, 2005
TORONTO--(BUSINESS WIRE)--Nov 29, 2005 - Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that it has officially launched Glumetza(TM) in Canada. ... - PharmaLive.com (press release),

Biovail launches Glumetza in Canada Nov 29, 2005
TORONTO (Reuters) - Biovail Corp. said on Tuesday it had launched Glumetza to treat Type 2 diabetes in Canada. Biovail said Glumetza ... - Metro Toronto,

Depomed, Biovail in potential deal on Glumetza Nov 23, 2005
Biovail Corp. (BVF.N: Quote) that could resolve a dispute between the two over the licensing agreement for Glumetza. Depomed said ... - Reuters Canada,

Depomed, Biovail in potential deal on Glumetza Nov 23, 2005
...agreement with Biovail Corp. that could resolve a dispute between the two over the licensing agreement for Glumetza. Depomed said the ... - Metro Toronto,

Biovail launches Glumetza in Canada Nov 29, 2005
TORONTO (Reuters) - Biovail Corp. (BVF.TO: Quote) (BVF.N: Quote) said on Tuesday it had launched Glumetza to treat Type 2 diabetes in Canada. ... - Reuters Canada,

Dear Subscriber to TheStreet.com Stocks Under $10, Nov 29, 2005
DEPO:Nasdaq) are trading some 10% higher today to $5.79 after Biovail (BVF:NYSE) announced that it officially launched diabetes drug Glumetza -- which was ... - TheStreet.com (subscription),

Dear Subscriber to TheStreet.com Stocks Under $10, Nov 17, 2005
...has filed a lawsuit against distribution partner Biovail (BVF:NYSE) related to a 2002 agreement that licensed DepoMed's diabetes treatment Glumetza to Biovail ... - TheStreet.com (subscription),

Depomed to Present at the New York Society of Security Analysts ... Dec 8, 2005
In addition, regulatory applications for once daily Glumetza(TM) (Metformin GR(R)) for the treatment of Type II diabetes have been approved in the US and Canada ... - Genetic Engineering News,

Stocks Under $10 Weekly Summary Dec 9, 2005
Continued execution by management in the coming quarters -- when its two FDA-approved drugs, Proquin XR for urinary tract infections and Glumetza for diabetes ... - TheStreet.com (subscription),

Depomed Announces Lawsuit Against Biovail for Breach of Contract Nov 16, 2005
...and its subsidiary, Biovail Laboratories International, relating to Biovail's breaches of the parties' 2002 license agreement, as amended, for Glumetza(TM), a ... - Genetic Engineering News,

Depomed Announces Non-Binding Term Sheet Agreement With Biovail ... Nov 23, 2005
NYSE:BVF) (TSX:BVF) which may lead to the resolution of the parties' ongoing contractual dispute related to the license agreement for Glumetza(TM), a once ... - Business Wire (press release),

Diabetics make each shot count Nov 25, 2005
A new drug called Glumetza may help. Glumetza, which is being launched this month by Biovail Pharmaceuticals, the first once-daily metforming medication. ... - Ottawa Sun,

Stocks Under $10 Weekly Summary Nov 18, 2005
...effects. As it stands now, DepoMed has two FDA-approved products -- Glumetza for diabetes and Proquin for urinary tract infections. ... - TheStreet.com (subscription),

Depomed Reports Third Quarter 2005 Financial Results; $55 Million ... Nov 9, 2005
...fees associated with the commercialization agreement for ProQuin(R) XR and a payment from Biovail Laboratories of $25 million for the US approval of Glumetza(TM ... - PharmaLive.com (press release),

Highlights of rising and falling US stocks Nov 29, 2005
Depomed (DEPO) shares ended Tuesday with a 13.3% gain after Biovail (BVF) launched Glumetza, a diabetes treatment developed in partnership with Depomed, in ... - Investor's Business Daily (subscription)

Stocks Under $10: F, VC, DEPO, BVF Nov 23, 2005
...that DepoMed (DEPO:Nasdaq) said this morning that it settled an ongoing contract dispute with Biovail (BVF:NYSE) over Type II diabetes treatment Glumetza. ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Dec 2, 2005
...target price. Also, DepoMed and Biovail announced the official launch of diabetes drug Glumetza in the Canadian market. Lastly, DepoMed ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Nov 25, 2005
...the market about the prospects of its Intentia purchase, and DepoMed (DEPO:Nasdaq) also settled a contract dispute over its Type II diabetes treatment, Glumetza ... - TheStreet.com (subscription),

Biovail stock drops 13 pct on generic antidepressant Nov 17, 2005
...filed a lawsuit against Biovail seeking damages and to terminate a license deal for its Glumetza treatment of Type II diabetes. ... - Metro Toronto,

Depomed, Biovail in talks to end diabetes treatment dispute Nov 23, 2005
16 alleging breaches of a licence agreement for Glumetza, a once-daily extended release formulation of metformin approved for the treatment of Type II diabetes ... - San Jose Business Journal,

Biovail Reports Third-Quarter 2005 Financial Results Nov 11, 2005
During the third quarter of 2005, following FDA approval of Glumetza(TM), Biovail paid $25.0 million to Depomed Inc. At the end ... - Business Wire (press release),

Dear Subscriber to TheStreet.com Stocks Under $10, Oct 4, 2005
...it has notified Biovail (BVF:Amex) that it is in breach of a distribution agreement because Biovail failed to bring DepoMed's diabetic drug Glumetza to market ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Oct 7, 2005
...agreement. The agreement called for Biovail to bring DepoMed's diabetes treatment Glumetza to market by Oct. 3. Investors interpreted ... - TheStreet.com (subscription),

Depomed Delivers Notice of Breach to Biovail Oct 3, 2005
...subsidiary, Biovail Laboratories Incorporated, outlining Biovail's material breaches of the parties' 2002 license agreement, as amended, for Glumetza(TM), a ... - Genetic Engineering News,

Dear Subscriber to TheStreet.com Stocks Under $10, Sep 27, 2005
Given that DepoMed has two products scheduled to be released by the end of the year -- Glumetza for diabetes and Proquin XR for urinary tract infections ... - TheStreet.com (subscription),

Depomed says Biovail breached agreement Oct 3, 2005
Depomed said the breach involves the failure of Biovail to make the first commercial sale of the 500-milligram strength Glumetza drug within 120 days of ... - BusinessWeek

Dear Subscriber to TheStreet.com Stocks Under $10, Sep 12, 2005
Growth Conference in California that its gastric retention (GR) drug-delivery system will be launched with two already approved drugs -- Glumetza for diabetes ... - TheStreet.com (subscription),

Stocks Under $10: DESC, IMAX, DEPO Sep 29, 2005
...firm Dawson James Securities reported this morning that DepoMed (DEPO:Nasdaq) will likely seek to repartner for its diabetes drub Glumetza -- which was ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary Sep 30, 2005
Given that DepoMed now has its first two products -- Glumetza for diabetes and Proquin XR for urinary track infection -- slated to come on the market in the ... - TheStreet.com (subscription),

Depomed Promotes Carl Pelzel to Executive Vice President, Chief ... Sep 27, 2005
In addition, regulatory applications for once daily Glumetza(TM) (metformin GR) for the treatment of Type II diabetes have been approved in the US and Canada. ... - Business Wire (press release),

The Expanding Pill Sep 29, 2005
Two weeks after Proquin's approval came a second FDA nod, for Glumetza, an expanding-pill version of metformin, a type 2 diabetes drug with $700 million in ... - Forbes

Stocks Under $10 Weekly Summary Sep 9, 2005
DepoMed has two drugs coming to market in the fourth quarter -- Glumetza for diabetes and antibiotic Ciprofloxacin -- and we expect the company to continue to ... - TheStreet.com (subscription),

Stocks Under $10 Weekly Summary 09 Sep 2005
DepoMed has two drugs coming to market in the fourth quarter -- Glumetza for diabetes and antibiotic Ciprofloxacin -- and we expect the company to continue to ... - TheStreet.com (subscription),

Dear Subscriber to TheStreet.com Stocks Under $10, Aug 29, 2005
...its ability in trials to limit nasty side effects and increase the efficacy of two already- marketed drugs, antibiotic Ciprofloxacin and diabetes drug Glumetza ... - TheStreet.com (subscription),

Depomed to Present at the ThinkEquity Partners Growth Conference Sep 7, 2005
In addition, regulatory applications for once daily Glumetza(TM) (Metformin GR(TM)) for the treatment of Type II diabetes have been approved in the US and ... - Business Wire (press release),

Stocks Under $10 Weekly Summary Sep 2, 2005
So far, DepoMed has signed deals for two FDA-approved drugs -- antibiotic Ciprofloxacin and diabetes treatment Glumetza -- to use its Gastric Retention system. ... - TheStreet.com (subscription),